全国服务咨询热线：
18438616290
18438616290
产品分类
Product Category详细介绍
| 品牌 | absin | CAS | 936623-90-4 |
|---|---|---|---|
| 分子式 | C24H29N5O3.C24H29NO5.5/2H2O.3Na | 纯度 | ≥98% |
| 分子量 | 915.98 | 货号 | abs47027992 |
| 规格 | 5mg | 供货周期 | 现货 |
| 主要用途 | is an orally bioavailable | 应用领域 | 化工,生物产业,农林牧渔,制药/生物制药,综合 |
LCZ696 936623-90-4
| 产品描述 | |
| 描述 | LCZ696, consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3. |
| 纯度 | ≥98% |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 别名 | 奥帕曲拉；缬sha坦；Sacubitril；valsartan |
| 外观 | white powder |
| 可溶性/溶解性 | DMSO : 28 mg/mL (30.6 mM) Ethanol : 9 mg/mL (9.82 mM), warmed Water : 92 mg/mL (100.4 mM) |
| 生物活性 | |
| 靶点 | RAAS |
| In vitro(体外研究) | LCZ696 is a single molecule that is comprised of molecular moieties of valsartan, an ARB, and AHU377, a neprilysin inhibitor (1:1 ratio). |
| In vivo(体内研究) | LCZ696 exerts a blood pressure lowering effect. Blood pressure reduction by LCZ696 is associated with a significant increase in urinary sodium excretion and sympathetic activity suppression. LCZ696 significantly ameliorates cardiac hypertrophy and inflammation, coronary arterial remodeling, and vascular endothelial dysfunction in high-salt loaded SHRcp compared with valsartan. The neprilysin inhibitor component of LCZ696, LBQ657, inhibits hypertrophy but not fibrosis. The angiotensin receptor blocker component of LCZ696, valsartan inhibits both hypertrophy and fibrosis. Dual valsartan+LBQ augment the inhibitory effects of valsartan and the highest doses completely abrogate angiotensin II-mediated effects. Pre-treatment with LCZ696 reduces the ischemic area. The decrease in cerebral blood flow in the peripheral region of the ischemic area is significantly attenuated by pre-treatment with LCZ696. LCZ696 pre-treatment significantly decreases the increase of superoxide anion production in the cortex on the ischemic side. |
| 研究领域 | |
| 研究领域 | Cardiovascular CancerCancer Metabolism CancerTumor biomarkers NeuroscienceEndocrine system Drug DiscoverySmall Molecule DrugLead Compound Discovery |
产品咨询
地址：上海市浦东新区新浩路58号申江科创园18栋
邮箱：lanwu@univ-bio.com
传真：